Physician profile
Jaclyn Fuller
NPI 1851668271
$11,883.43
in general payments reported to CMS, 2019-2025
36 companies · $2,873 in 2025
The $2,873 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.43 · 2022: $2,634 · 2023: $2,886 · 2024: $3,393 · 2025: $2,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,128 · Education: $23.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,127.96 |
| Education | $23.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,825.34 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,271.28 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $940.24 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $934.32 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $853.48 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $610.15 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $517.36 | 2022-2024 | Linzess |
| Gilead Sciences, INC. | $461.76 | 2022-2025 | |
| Qol Medical, LLC | $443.33 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $443.10 | 2022-2025 | |
| Madrigal Pharmaceuticals | $432.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $285.83 | 2022-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $239.49 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $216.38 | 2024-2025 | Voquezna |
| Pfizer INC. | $167.51 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $138.55 | 2022 | |
| Nestle Healthcare Nutrition INC. | $121.20 | 2022-2023 | |
| Celgene Corporation | $112.52 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $100.56 | 2023-2025 | Iqirvo, Bylvay |
| Braintree Laboratories, INC. | $87.96 | 2022-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $83.32 | 2022-2023 | Clenpiq, Rebyota |
| Intercept Pharmaceuticals, INC. | $80.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $71.33 | 2022-2023 | Dificid |
| Celltrion USA INC. | $66.67 | 2024-2025 | Zymfentra, Vegzelma |
| Redhill Biopharma INC. | $60.67 | 2022-2023 | |
| Lilly USA, LLC | $53.91 | 2023-2025 | Omvoh |
| Shield Therapeutics INC | $37.44 | 2023-2024 | Accrufer |
| Boston Scientific Corporation | $34.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.32 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $31.38 | 2023 | Idacio |
| Janssen Scientific Affairs, LLC | $23.46 | 2024 | Stelara |
| Exact Sciences Corporation | $19.04 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $18.19 | 2022 | |
| Daiichi Sankyo INC. | $17.33 | 2022 | |
| Ucb, INC. | $17.14 | 2024 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.